<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00507494</url>
  </required_header>
  <id_info>
    <org_study_id>DNTx</org_study_id>
    <nct_id>NCT00507494</nct_id>
  </id_info>
  <brief_title>Influence of Pioglitazone for Renal Transplant Function in Diabetics</brief_title>
  <official_title>Influence of Pioglitazone for Renal Transplant Function in Diabetics - a Double Blind Randomised Placebo Controlled Cross Over Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universität Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Technische Universität Dresden</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether pioglitazone is able to prevent the progression
      of diabetic nephropathy in kidney transplant recipients with diabetes mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 30 % of kidney transplant recipients will develop diabetes mellitus. This condition is
      a risk factor for graft dysfunction, graft loss and increased mortality of patients.
      Inflammatory reactions within the graft and proteinuria are considered as pathogenetic
      mechanisms.

      Recent studies indicated that pioglitazone might have beneficial effects on the urinary
      protein excretion of type 2 diabetic patients with diabetic nephropathy and was able to
      reduce systemic inflammation.

      This lead to the hypothesis that pioglitazone could improve proteinuria of kidney transplant
      patients with diabetes.

      Comparison: Effects of pioglitazone vs. placebo on proteinuria and renal function of kidney
      transplant recipients in a cross over study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>proteinuria</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>efficacy: filtration fraction, renal nitric oxide bioavailability, insulin resistance, platelet function safety: tolerability, plasma glucose, body weight, edema</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <condition>Diabetes Mellitus</condition>
  <condition>Kidney Transplantation</condition>
  <condition>Proteinuria</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pioglitazone</intervention_name>
    <description>Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  kidney transplantation(&gt; 6 months ago) ; stable graft function

          -  diabetes mellitus type 2

          -  acceptable glycemia (HbA1c &lt; 8%)

          -  creatinin clearance (MDRD)&gt;30 ml/min 1,73m²)

          -  proteinuria &gt; 30 mg/24 hr

        Exclusion Criteria:

          -  type 1 diabetes

          -  pregnant or breast feeding women

          -  congestive heart failure (&gt;stage 1 NYHA)

          -  creeping creatinin

          -  treatment for rejection within 3 months prior to inclusion

          -  ALT, AST &gt; 2.5 fold the upper limit of normal

          -  uncontrolled hypertension

          -  hypo- or hyperthyroidism
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Gross, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nephrology, Department of Medicine, University hospital Dresden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology, Department of Medicine, university hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>October 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2007</study_first_submitted>
  <study_first_submitted_qc>July 25, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 26, 2007</study_first_posted>
  <last_update_submitted>October 27, 2011</last_update_submitted>
  <last_update_submitted_qc>October 27, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 28, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>posttransplant diabetes mellitus</keyword>
  <keyword>kidney transplantation</keyword>
  <keyword>filtration fraction</keyword>
  <keyword>proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Proteinuria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pioglitazone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

